UF Innovate | Accelerate graduate Oragenics, Inc., a clinical-stage biotechnology company developing brain-targeted therapeutics through proprietary intranasal delivery technology, previewed its targeted milestones for 2026. Oragenics is advancing its lead candidate ONP-002, a novel intranasal neurosteroid, through clinical studies as the potential first and only pharmacological treatment for concussion and mild traumatic brain injury (mTBI).
Oragenics’ CEO Janet Huffman commented, “Through successful operational, regulatory and financial execution over the past year, we achieved key strategic milestones that secured the clinical infrastructure required to enter a Phase 2 clinical trial of ONP-002 in Australia this year. We have demonstrated financial discipline and transparency in support of our clinical development program, and the Company is now well-positioned to advance ONP-002 toward meaningful value-creating milestones.
Read more about Oragenics Targets Projected $9 Billion Market by Advancing First and Only Clinical-Stage Concussion and Mild Traumatic Brain Injury Therapy.
